GPT-Rosalind
GPT-Rosalind is OpenAI's life-sciences frontier model, updated to improve drug discovery, genomics, quantitative biology, and wet-lab troubleshooting while using approximately 31% fewer tokens than GPT-5.5 on long-horizon genomics analyses. Its research preview is now open to eligible organizations globally, with Novo Nordisk joining partners Amgen, Moderna, the Allen Institute, and Thermo Fisher.